23 research outputs found
PO-0857: GTV-based prescription and Monte Carlo treatment planning in Cyberknife treatments for lung lesions
n/
Re: (11C)Choline Positron Emission Tomography/Computerized Tomography to Restage Prostate Cancer Cases With Biochemical Failure After Radical Prostatectomy and No Disease Evidence on Conventional Imaging G. Giovacchini, M. Picchio, A. Briganti, C. Cozzarini, V. Scattoni, A. Salonia, C. Landoni, L. Gianolli, N. Di Muzio, P. Rigatti, F. Montorsi and C. Messa J Urol 2010; 184: 938-943
EP-1758: Cyberknife Stereotactic Radiation Therapy for lung cancer: role of the LOT simulation.
Does the treated volume have an impact on set-up errors in the rapidarcCTM treatment of prostate carcinoma?
CyberKnife robotic image-guided stereotactic radiotherapy for oligometastic cancer : a prospective evaluation of 95 patients/118 lesions
PURPOSE: To evaluate the outcome of robotic CyberKnife (Accuray Inc. Sunnyvale, USA)-based stereotactic radiotherapy (CBK-SRT) for oligometastic cancer patients.
PATIENTS AND METHODS: Between May 2007 and December 2009, 95 patients with a total of 118 lesions underwent CBK-SRT (median dose 24 Gy in 3 fractions). Inclusion criteria: adult patients with limited volume cancer; suitability for SRT but not for other local therapies. Primary diagnoses included breast, lung, head and neck, gastrointestinal and other malignancies. Prostate cancer patients were excluded. Concomitant systemic therapy was given in 40\u2009% of cases and median follow-up was 12 months. Toxicity and tumor response were evaluated using the Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer (RTOG/EORTC) Scale and Response Evaluation Criteria in Solid Tumors RECIST.
RESULTS: Toxicity was rare and observed mainly in patients with comorbidities or uncontrolled cancer. Out of 87 evaluable lesions, complete radiological response, partial response, stabilization and progressive disease were observed in 15 (17\u2009%), 25 (29\u2009%), 34 (39\u2009%) and 13 (15\u2009%) lesions, respectively. Upon restricting the analysis to lesions treated with CBK-SRT alone (no concomitant therapy), response- and local control (LC) rates remained similar. Actuarial 3-year in-field progression-free survival- (i.e. LC), progression-free survival- (PFS) and overall-survival (OS) rates were 67.6, 18.4, and 31.2\u2009%, respectively. LC was reduced in cases of early recurrence. OS- and cause-specific survival (CSS) rates were significantly lower in patients treated for visceral lesions. Failures were predominantly out-field.
CONCLUSION: CBK-SRT is a feasible therapeutic approach for oligometastastic cancer patients that provides long-term in-field tumor control with a low toxicity profile. Further investigations should focus on dose escalation and optimization of the combination with systemic therapies
CyberKnife robotic image-guided stereotactic radiotherapy for oligometastic cancer: A prospective evaluation of 95 patients/118 lesions
PURPOSE: To evaluate the outcome of robotic CyberKnife (Accuray Inc. Sunnyvale, USA)-based stereotactic radiotherapy (CBK-SRT) for oligometastic cancer patients.
PATIENTS AND METHODS: Between May 2007 and December 2009, 95 patients with a total of 118 lesions underwent CBK-SRT (median dose 24 Gy in 3 fractions). Inclusion criteria: adult patients with limited volume cancer; suitability for SRT but not for other local therapies. Primary diagnoses included breast, lung, head and neck, gastrointestinal and other malignancies. Prostate cancer patients were excluded. Concomitant systemic therapy was given in 40\u2009% of cases and median follow-up was 12 months. Toxicity and tumor response were evaluated using the Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer (RTOG/EORTC) Scale and Response Evaluation Criteria in Solid Tumors RECIST.
RESULTS: Toxicity was rare and observed mainly in patients with comorbidities or uncontrolled cancer. Out of 87 evaluable lesions, complete radiological response, partial response, stabilization and progressive disease were observed in 15 (17\u2009%), 25 (29\u2009%), 34 (39\u2009%) and 13 (15\u2009%) lesions, respectively. Upon restricting the analysis to lesions treated with CBK-SRT alone (no concomitant therapy), response- and local control (LC) rates remained similar. Actuarial 3-year in-field progression-free survival- (i.e. LC), progression-free survival- (PFS) and overall-survival (OS) rates were 67.6, 18.4, and 31.2\u2009%, respectively. LC was reduced in cases of early recurrence. OS- and cause-specific survival (CSS) rates were significantly lower in patients treated for visceral lesions. Failures were predominantly out-field.
CONCLUSION: CBK-SRT is a feasible therapeutic approach for oligometastastic cancer patients that provides long-term in-field tumor control with a low toxicity profile. Further investigations should focus on dose escalation and optimization of the combination with systemic therapies
EP-1175: Role of Radiotherapy in the management of metastases from salivary gland carcinoma
3D-conformal hypofractionated radiotherapy for prostate cancer with daily transabdominal ultrasonography prostate localization: toxicity and outcome of a pilot study
Aims and background. To evaluate the feasibility, toxicity and patient outcome of hypofractionated 3-dimensional conformal radiotherapy for low- and intermediate-risk prostate cancer, using daily an ultrasound targeting system (BAT\u2122). Methods. Between May 2005 and October 2006, 25 patients (cT1-T2, GS 647,mean initial PSA = 7.06 ng/ml) received a dose of 72 Gy in 30 fractions. Only the prostate was included in the clinical target volume. Immediately before each radiotherapy session, BAT\u2122 ultrasound alignment was performed. Acute and late toxicity was evaluated according to the Radiation Therapy Oncology Group criteria; the Phoenix definition (PSA = nadir + 2 ng/ml) was applied to define biochemical failure. BAT\u2122 localization data were provided for 300 out of 750 procedures. Results. No interruptions in 3-dimensional conformal radiotherapy due to toxicity were registered. There was no acute rectal toxicity in 52% of patients; 28% had G1, 16% had G2, and 1 patient had a G3 event. No acute urinary toxicity was observed in 28% of the patients. G1 toxicity occurred in 40%, G2 in 28%, and G3 in 1 patient; no G4 event was observed. With an average follow-up of 45 months, one biochemical relapse was observed; late toxicity showed an excellent profile: 78% of the patients had no rectal toxicity, 16% had G1, and 1 patient had G2 toxicity. Most of the patients (68%) had no late urinary complications, whereas 32% had G1 toxicity. Localization data showed systematic and random errors in relation to some procedure biases. Conclusions. Promising tumor control and toxicity profile were observed with this mildly hypofractionated BAT-based 3-dimensional conformal radiotherapy. Free full text available at www.tumorionline.it
Early outcome of volumetric modulated rapidarcCTM hypofractionated post-prostatectomy radiotherapy of prostate cancer
Image guided hypofractionated radiotherapy and quality of life for localized prostate cancer : prospective longitudinal study in 337 patients
Purpose: We prospectively analyzed quality of life in a cohort of patients with prostate
cancer undergoing a course of hypofractionated image guided radiotherapy.
Materials and Methods: Between August 2006 and January 2011, 337 patients
with a median age of 73 years who had cT1-T2N0M0 prostate cancer were eligible
for this prospective, longitudinal study of hypofractionated image guided radiotherapy
(70.2 Gy/26 fractions) using 1 of 3 image guided radiotherapy modalities
(transabdominal ultrasound, x-ray or cone beam computerized tomography)
available in our radiation oncology department. Patients completed 4 questionnaires
before treatment, and 6, 12 and 24 months later, including the International
Index of Erectile Function-5, International Prostate Symptom Score, and
EORTC (European Organization for Research and Treatment of Cancer) prostate
cancer specific QLQ-PR25 and QLQ-C30.
Results: Patient followup was updated to at least the last questionnaire time point.
Median followup was 19 months. Significant deterioration in erectile function on the
International Index of Erectile Function-5 was documented with time only in patients
without androgen deprivation (p 0.0002). No change with time was observed in
urinary symptom related quality of life on the QLQ-PR25 or International Prostate
Symptom Score. Slight deterioration in QLQ-PR25 bowel symptom related quality of life
was observed (p 0.02). Overall QLQ-C30 Global Health Status improved with time
(p 0.03). On univariate analysis it significantly correlated with the maximum RTOG
(Radiation Therapy Oncology Group)/EORTC urinary and bowel late toxicity scores
after radiotherapy.
Conclusions: The regimen of hypofractionated image guided radiotherapy with
multiple imaging modalities adopted in our radiation oncology department for
localized prostate cancer might be a successful strategy for dose escalation with
a limited impact on different aspects of quality of life with time